These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28376088)

  • 21. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
    Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
    Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
    Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
    Mao TL; Fan MH; Dlamini N; Liu CL
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
    Han GH; Shim JE; Yun H; Kim J; Kim JH; Cho H
    J Gene Med; 2022 Nov; 24(11):e3452. PubMed ID: 36170157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
    Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
    Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosomal instability and aneuploidy as causes of cancer drug resistance.
    Lukow DA; Sheltzer JM
    Trends Cancer; 2022 Jan; 8(1):43-53. PubMed ID: 34593353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
    Gorringe KL; Chin SF; Pharoah P; Staines JM; Oliveira C; Edwards PA; Caldas C
    Carcinogenesis; 2005 May; 26(5):923-30. PubMed ID: 15677628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
    Pan ZM; Tan FC; Chen CX; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
    [No Abstract]   [Full Text] [Related]  

  • 33. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.
    Li RN; Liu B; Li XM; Hou LS; Mu XL; Wang H; Linghu H
    Sci Rep; 2017 Aug; 7(1):9285. PubMed ID: 28839145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-cell RNA sequencing reveals the impact of chromosomal instability on glioblastoma cancer stem cells.
    Zhao Y; Carter R; Natarajan S; Varn FS; Compton DA; Gawad C; Cheng C; Godek KM
    BMC Med Genomics; 2019 May; 12(1):79. PubMed ID: 31151460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new assay for measuring chromosome instability (CIN) and identification of drugs that elevate CIN in cancer cells.
    Lee HS; Lee NC; Grimes BR; Samoshkin A; Kononenko AV; Bansal R; Masumoto H; Earnshaw WC; Kouprina N; Larionov V
    BMC Cancer; 2013 May; 13():252. PubMed ID: 23694679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.